H. Lundbeck A/S- (OTCMKTS:HLUYY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

H. Lundbeck A/S- (HLUYY) opened at $47.66 on Thursday. H. Lundbeck A/S- has a one year low of $38.21 and a one year high of $66.67. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.93 and a current ratio of 1.21. The firm has a market capitalization of $9,530.00, a price-to-earnings ratio of 22.38, a P/E/G ratio of 1.00 and a beta of 0.19.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/h-lundbeck-as-hluyy-stock-rating-lowered-by-zacks-investment-research/1766921.html.

H. Lundbeck A/S- Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.